Cyclo Therapeutics Inc
NASDAQ:CYTH
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.64
1.9
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CYTH stock under the Base Case scenario is 5.6 USD. Compared to the current market price of 0.74 USD, Cyclo Therapeutics Inc is Undervalued by 87%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Cyclo Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CYTH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Cyclo Therapeutics Inc
Balance Sheet Decomposition
Cyclo Therapeutics Inc
Current Assets | 4.5m |
Cash & Short-Term Investments | 1.1m |
Receivables | 83.7k |
Other Current Assets | 3.2m |
Non-Current Assets | 267.7k |
PP&E | 267.7k |
Current Liabilities | 9.8m |
Accounts Payable | 5.5m |
Accrued Liabilities | 1.6m |
Short-Term Debt | 2.7m |
Non-Current Liabilities | 12.4k |
Other Non-Current Liabilities | 12.4k |
Earnings Waterfall
Cyclo Therapeutics Inc
Revenue
|
1.1m
USD
|
Cost of Revenue
|
-95.6k
USD
|
Gross Profit
|
1m
USD
|
Operating Expenses
|
-22.2m
USD
|
Operating Income
|
-21.2m
USD
|
Other Expenses
|
416.9k
USD
|
Net Income
|
-20.7m
USD
|
Free Cash Flow Analysis
Cyclo Therapeutics Inc
USD | |
Free Cash Flow | USD |
CYTH Profitability Score
Profitability Due Diligence
Cyclo Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Cyclo Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
CYTH Solvency Score
Solvency Due Diligence
Cyclo Therapeutics Inc's solvency score is 26/100. The higher the solvency score, the more solvent the company is.
Score
Cyclo Therapeutics Inc's solvency score is 26/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CYTH Price Targets Summary
Cyclo Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for CYTH is 0.97 USD with a low forecast of 0.96 USD and a high forecast of 1 USD.
Dividends
Current shareholder yield for CYTH is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CYTH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 9 full-time employees. The company went IPO on 2004-02-27. The firm's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. The company is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The firm's product lines include Trappsol and Aquaplex. The company sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The firm also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
Contact
IPO
Employees
Officers
The intrinsic value of one CYTH stock under the Base Case scenario is 5.6 USD.
Compared to the current market price of 0.74 USD, Cyclo Therapeutics Inc is Undervalued by 87%.